Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine in MDS and AML
NCT01261312Phase 2Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Jan 2011
- Primary completion
- Jul 2016
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of guadecitabine in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) (13 arms), sponsored by Astex Pharmaceuticals. Primary endpoints: Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation, Number of Participants With Dose Limiting Toxicity and 2 more. Started Jan 2011; status: completed.
02
Drugs
guadecitabine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01261312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01261312.